SAREPTA THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $1.19M, a 78.95% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $6.64M, a 1.28% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $5.64M, a 2.02% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-03-31 was $6.56M, a 25.47% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $7.83M, a 35.82% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $12.21M, a 13.42% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $10.76M, a 44.06% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $7.47M, a 4.71% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $7.83M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.19M 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $6.64M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $12.21M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $5.64M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $6.56M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $10.76M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $5.53M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $5.23M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $7.47M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $3.48M 10-Q · filed 2023-11-01 | |
| 2022-03-31 | $3.99M 10-Q · filed 2023-11-01 | |
| 2021-12-31 | $7.84M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $3.30M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $4.54M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $7.46M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $3.67M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $3.79M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $5.08M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $2.75M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $2.33M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $2.31M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $1.55M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $756.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $1.43M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $1.58M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $879.00K 10-K · filed 2018-03-01 | |
| 2014-12-31 | $1.01M 10-K · filed 2017-02-28 | |
| 2009-12-31 | $85.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |